192 related articles for article (PubMed ID: 31002702)
1. Effect of HIV-exposure and timing of anti-retroviral treatment on immunogenicity of trivalent live-attenuated polio vaccine in infants.
Moonsamy S; Suchard M; Madhi SA
PLoS One; 2019; 14(4):e0215079. PubMed ID: 31002702
[TBL] [Abstract][Full Text] [Related]
2. Reduced Poliovirus vaccine neutralising-antibody titres in infants with maternal HIV-exposure.
Sanz-Ramos M; Manno D; Kapambwe M; Ndumba I; Musonda KG; Bates M; Chibumbya J; Siame J; Monze M; Filteau S; Gompels UA;
Vaccine; 2013 Apr; 31(16):2042-9. PubMed ID: 23474309
[TBL] [Abstract][Full Text] [Related]
3. Immune responses to oral poliovirus vaccine in HIV-exposed uninfected Zimbabwean infants.
Church JA; Rukobo S; Govha M; Carmolli MP; Diehl SA; Chasekwa B; Ntozini R; Mutasa K; Humphrey JH; Kirkpatrick BD; Prendergast AJ
Hum Vaccin Immunother; 2017 Nov; 13(11):2543-2547. PubMed ID: 28857649
[TBL] [Abstract][Full Text] [Related]
4. Infectious morbidity of breastfed, HIV-exposed uninfected infants under conditions of universal antiretroviral therapy in South Africa: a prospective cohort study.
le Roux SM; Abrams EJ; Donald KA; Brittain K; Phillips TK; Zerbe A; le Roux DM; Kroon M; Myer L
Lancet Child Adolesc Health; 2020 Mar; 4(3):220-231. PubMed ID: 31932246
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a combined schedule of trivalent oral and inactivated polio vaccines in South African infants.
Moonsamy S; Suchard MS; Madhi SA
Expert Rev Vaccines; 2019 Jul; 18(7):751-754. PubMed ID: 31194605
[No Abstract] [Full Text] [Related]
6. Growth trajectories of breastfed HIV-exposed uninfected and HIV-unexposed children under conditions of universal maternal antiretroviral therapy: a prospective study.
le Roux SM; Abrams EJ; Donald KA; Brittain K; Phillips TK; Nguyen KK; Zerbe A; Kroon M; Myer L
Lancet Child Adolesc Health; 2019 Apr; 3(4):234-244. PubMed ID: 30773459
[TBL] [Abstract][Full Text] [Related]
7. Effect of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected children on immunogenicity of vaccines during infancy.
Simani OE; Izu A; Violari A; Cotton MF; van Niekerk N; Adrian PV; Madhi SA
AIDS; 2014 Feb; 28(4):531-41. PubMed ID: 24468996
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine.
Moriniere BJ; van Loon FP; Rhodes PH; Klein-Zabban ML; Frank-Senat B; Herrington JE; Pallansch MA; Patriarca PA
Lancet; 1993 Jun; 341(8860):1545-50. PubMed ID: 8099637
[TBL] [Abstract][Full Text] [Related]
9. Effect of in-utero HIV exposure and antiretroviral treatment strategies on measles susceptibility and immunogenicity of measles vaccine.
Simani OE; Adrian PV; Violari A; Kuwanda L; Otwombe K; Nunes MC; Cotton MF; Madhi SA
AIDS; 2013 Jun; 27(10):1583-91. PubMed ID: 24047763
[TBL] [Abstract][Full Text] [Related]
10. Delayed BCG immunization does not alter antibody responses to EPI vaccines in HIV-exposed and -unexposed South African infants.
Hesseling AC; Blakney AK; Jones CE; Esser MM; de Beer C; Kuhn L; Cotton MF; Jaspan HB
Vaccine; 2016 Jul; 34(32):3702-9. PubMed ID: 27055019
[TBL] [Abstract][Full Text] [Related]
11. Oral polio vaccine response in the MAL-ED birth cohort study: Considerations for polio eradication strategies.
Pan WK; Seidman JC; Ali A; Hoest C; Mason C; Mondal D; Knobler SL; Bessong P;
Vaccine; 2019 Jan; 37(2):352-365. PubMed ID: 30442479
[TBL] [Abstract][Full Text] [Related]
12. Lower birth weight-for-age and length-for-age z-scores in infants with in-utero HIV and ART exposure: a prospective study in Cape Town, South Africa.
Nyemba DC; Kalk E; Madlala HP; Malaba TR; Slogrove AL; Davies MA; Boulle A; Myer L; Powis KM
BMC Pregnancy Childbirth; 2021 May; 21(1):354. PubMed ID: 33947351
[TBL] [Abstract][Full Text] [Related]
13. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
[TBL] [Abstract][Full Text] [Related]
14. Measles Immunity at 4.5 Years of Age Following Vaccination at 9 and 15-18 Months of Age Among Human Immunodeficiency Virus (HIV)-infected, HIV-exposed-uninfected, and HIV-unexposed Children.
Mutsaerts EAML; Nunes MC; van Rijswijk MN; Klipstein-Grobusch K; Otwombe K; Cotton MF; Violari A; Madhi SA
Clin Infect Dis; 2019 Aug; 69(4):687-696. PubMed ID: 30418528
[TBL] [Abstract][Full Text] [Related]
15. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants.
Wright PF; Connor RI; Wieland-Alter WF; Hoen AG; Boesch AW; Ackerman ME; Oberste MS; Gast C; Brickley EB; Asturias EJ; Rüttimann R; Bandyopadhyay AS
Lancet Infect Dis; 2016 Dec; 16(12):1377-1384. PubMed ID: 27638357
[TBL] [Abstract][Full Text] [Related]
16. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
[TBL] [Abstract][Full Text] [Related]
17. Pediatric HIV Infection and Decreased Prevalence of OPV Point Mutations Linked to Vaccine-associated Paralytic Poliomyelitis.
Halpern MS; Altamirano J; Maldonado Y
Clin Infect Dis; 2018 Oct; 67(suppl_1):S78-S84. PubMed ID: 30376083
[TBL] [Abstract][Full Text] [Related]
18. Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis.
Swartz TA; Handsher R; Manor Y; Stoeckel P; Barkay A; Mendelson E; Leventhal A
Vaccine; 1998 Dec; 16(20):2090-5. PubMed ID: 9796069
[TBL] [Abstract][Full Text] [Related]
19. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines.
Steele AD; De Vos B; Tumbo J; Reynders J; Scholtz F; Bos P; de Beer MC; Van der Merwe CF; Delem A
Vaccine; 2010 Sep; 28(39):6542-8. PubMed ID: 18786585
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial.
Estívariz CF; Jafari H; Sutter RW; John TJ; Jain V; Agarwal A; Verma H; Pallansch MA; Singh AP; Guirguis S; Awale J; Burton A; Bahl S; Chatterjee A; Aylward RB
Lancet Infect Dis; 2012 Feb; 12(2):128-35. PubMed ID: 22071249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
